Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von Merck Gesellschaft mbH.
ONTARGET - Ongoing telmisartan alone and in combination with ramipril global endpoint trial und TRANSCEND - Telmisartan randomized assessment study in ACE-I intolerant subjects with cardiovascular disease (30 Abbildungen)
Übersicht
Gesamtpräsentation zum Download (rechte Maustaste und "Ziel speichern unter..." klicken)


Zum ersten Bild Abb. 15: ONTARGET - participating countries Abb. 16: ONTARGET will be the largest ARB trial to date Abb. 17: ONTARGET - patient profile Aktuelles Bild - Abb. 18: ONTARGET - study design Abb. 19: ONTARGET - study design Abb. 20: ONTARGET - time line Abb. 21: ONTARGET - primary end point Zum letzten Bild
Abbildung 18: ONTARGET - study design
ONTARGET is a double-blind, double-dummy, parallel-group study. ONTARGET will compare three treatment groups: + telmisartan 80 mg once daily + ramipril 10 mg once daily + a combination of telmisartan 80 mg and ramipril 10 mg once daily. The full dose of ramipril will only be given after forced titration from 2.5->5->10 mg per day due to concerns over first-dose hypotension.
 
ONTARGET - study design
Vorheriges Bild Nächstes Bild   


Abbildung 18: ONTARGET - study design
ONTARGET is a double-blind, double-dummy, parallel-group study. ONTARGET will compare three treatment groups: + telmisartan 80 mg once daily + ramipril 10 mg once daily + a combination of telmisartan 80 mg and ramipril 10 mg once daily. The full dose of ramipril will only be given after forced titration from 2.5->5->10 mg per day due to concerns over first-dose hypotension.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung